AMENDMENTS TO THE CLAIMS:

18. (Currently amended) A transdermal therapeutic system comprising a self-adhesive matrix layer containing the free base (-)-5,6,7,8-tetrahydro-6-[propyl-1[2-(2-thienyl) ethyl]amino]-1-naphthalenol in an amount effective for the treatment of the symptoms of Parkinson's syndrome, wherein the matrix is based on a ~~non-aqueous~~ substantially water-free, acrylate-based or silicone-based polymer adhesive system having a solubility of ≥5% (w/w) for the free base (-)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl) ethyl]-amino]-1-~~napthalenol~~ naphthalenol, all of said free base being present in the matrix substantially in the absence of water; a backing layer inert to the components of the matrix layer; and a protective foil or sheet covering the matrix layer to be removed prior to use.

19. (Previously presented) The transdermal therapeutic system of claim 18 further comprising <0.5% (w/w) inorganic silicate particulates in the matrix layer.

20. (Previously presented) The transdermal therapeutic system of claim 18 further comprising <0.05% (w/w) inorganic silicate particulates in the matrix layer.

21. (Previously presented) The transdermal therapeutic system of claim 18 wherein the acrylate-based polymer adhesive in the matrix layer contains at least two monomers selected from the group of acrylic acid, acrylamide,

hexylacrylate, 2-ethylhexylacrylate, hydroxyethylacrylate, octylacrylate, butylacrylate, methylacrylate, glycidylacrylate, methacrylic acid, methacrylamide, hexylmethacrylate, 2-ethyhexylmethacrylate, octylmethacrylate, methylmethacrylate, glycidylmethacrylate, vinylacetate and vinylpyrrolidone.

22. (Previously presented) The transdermal therapeutic system of claim 18 wherein the silicone-based polymer adhesive in the matrix layer further comprises additives to enhance the solubility of (–)–5,6,7,8–tetrahydro–6–[propyl–[2–(2–thienyl) ethyl] amino]–1–naphthalenol in the form of hydrophilic polymers or glycerol or glycerol derivatives.

23. (Previously presented) The transdermal therapeutic system of claim 21 wherein the acrylate-based polymer contains between 10 to 40% (w/w) (–)– 5,6,7,8–tetrahydro–6–[propyl–[2-(2-thienyl) ethyl]–amino]–1–naphthalenol.

24. (Previously presented) The transdermal therapeutic system of claim 22 wherein the silicone-based polymer adhesive contains between 5 to 25% (w/w) (–)–5,6,7,8–tetrahydro–6–[propyl–[2–(2–thienyl) ethyl]–amino]–1–naphthalenol.

25. (Previously presented) The transdermal therapeutic system of claim 23 further comprising substances which enhance the permeation of (–)–5,6,7,8–tetrahydro–6–[propyl–[2–(2–thienyl) ethyl] amino]–1–naphthalenol into the human skin.

26. (Previously presented) The transdermal therapeutic system of claim 24 further comprising substances which enhance the permeation of (–)–5,6,7,8–tetrahydro–6–[propyl–[2–(2–thienyl) ethyl] amino]–1–naphthalenol into the human skin.

27. (Previously presented) The transdermal therapeutic system of claim 25 wherein the permeation-enhancing substance is selected from the group of fatty alcohols, fatty acids, fatty acid esters, fatty acid amides, glycerol or its derivatives, N-methyl-pyrrolidone, terpenes, and terpene derivatives.

28. (Previously presented) The transdermal therapeutic system of claim 26 wherein the permeation-enhancing substance is selected from the group of fatty alcohols, fatty acids, fatty acid esters, fatty acid amides, glycerol or its derivatives, N-methyl-pyrrolidone, terpenes, and terpene derivatives.

29. (Previously presented) The transdermal therapeutic system of claim 27 wherein the permeation-enhancing substance is oleic acid or oleyl alcohol.

30. (Previously presented) The transdermal therapeutic system of claim 28 wherein the permeation-enhancing substance is oleic acid or oleyl alcohol.

31. (Previously presented) The transdermal therapeutic system of claim 22, wherein the hydrophilic polymer is selected from the group of polyvinylpyrrolidone, a copolymer of vinylpyrrolidone and vinylacetate,

polyethyleneglycol, polypropylene glycol, and a copolymer of ethylene and vinylacetate.

32. (Previously presented) The transdermal therapeutic system of claim 31 wherein the hydrophilic polymer is soluble polyvinylpyrrolidone, and wherein the soluble polyvinylpyrrolidone is present in the active substance-containing matrix layer at a concentration of between 1.5 and 5% (w/w).

33. (Previously presented) The transdermal system of claim 18 wherein the matrix further comprises inert fillers to improve cohesion.

34. - 41. (cancelled)